[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336169-105":59,"doc-detail-336169-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","review-of-patient-reported-outcomes-pros-and-non-pros-in-randomized-controlled-trials-addressing-headneck-cancers","Review of patient-reported outcomes (PROs) and non-PROs in randomized controlled trials addressing head/neck cancers","","Background: Assess the frequency of patient-reported outcomes (PROs) and non-PROs in randomized controlled trials (RCTs) addressing head/neck cancers. Methods: RCTs of interventions for head/neck cancers were included; PubMed searches were run on September 16, 2022 across three publication periods (2000–2002, 2010–2012, 2020–2022). Outcomes were extracted and grouped into PROs and non-PROs, and temporal reporting trends were analyzed. Results: Non-PROs decreased (40% to 22%) while PROs increased (5% to 19%) over 20 years, with combined reporting stability (55% to 58%). A wide variety of instruments was identified. Conclusions: PRO types have grown and are more frequently reported in newer RCTs; trials combining PROs and non-PROs are most prevalent.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/review-of-patient-reported-outcomes-pros-and-non-pros-in-randomized-controlled-trials-addressing-headneck-cancers/336169/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/review-of-patient-reported-outcomes-pros-and-non-pros-in-randomized-controlled-trials-addressing-headneck-cancers/336169.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s primary objective regarding head and neck cancer trials?","Question",{"text":112,"@type":113},"To map and assess how frequently patient-reported outcomes (PROs) and non-PROs appear in randomized controlled trials for head/neck cancers, including whether reporting changed over time.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were studies and follow-up periods selected for inclusion?",{"text":117,"@type":113},"Randomized controlled trials of interventions for head/neck cancers were included, with supportive and side-effect-related interventions also considered. When multiple follow-ups existed, the article with the longest follow-up was chosen, while other designs and non-English articles were excluded.",{"name":119,"@type":110,"acceptedAnswer":120},"What trends in PRO and non-PRO reporting were observed over the 20-year period?",{"text":121,"@type":113},"The frequency of non-PROs fell from 40% to 22%, while PROs increased from 5% to 19%. Reporting that included both PROs and non-PROs remained relatively stable, ranging from 55% to 58%.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336169,1790194917,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","DOI: 10. 1002/cam4 .7036  \nREVIEW  \nReview of patient-reported outcomes (PROs) and  \nnon-PROs in randomized controlled trials addressing head/ neck cancers  \nMichelle Gode  | Clovis Mariano Faggion Jr  \nDepartment of Periodontology and Operative Dentistry, Faculty of Dentistry, University Hospital Münster, Münster, Germany  \nCorrespondence  \nClovis Mariano Faggion Jr, Faculty of Dentistry, University Hospital Münster, Waldeyerstraße 30, 48149 Münster, Germany.  \nEmail: [clovisfaggion@yahoo.com](clovisfaggion@yahoo.com) and [clovis.faggion@ukmuenster.de](clovis.faggion@ukmuenster.de)  \n1 | INTRODUCTION  \nAbstract  \nBackground: To assess the frequency of patient-reported outcomes (PROs) and non-PROs in randomized controlled trials (RCTs) addressing head/neck cancers. Methods: We included RCTs about interventions to treat head/neck cancers. PubMed was searched on September 16, 2022 and included studies published during three periods (2000–2002, 2010–2012, and 2020–2022) . Data on types of outcomes and instruments to measure them were extracted and organized into PROsand non-PROs, and temporal trends for reporting outcomes were determined.  \nResults: There was a reduction in the frequency of non-PROs (40% to 22%) and an increase in PROs (5% to 19%) over 20 years. The frequency of reporting both non-PROs and PROs seemed to be stable over the same period (55% to 58%) . A great variety of instruments to measure PROs and non-PROs was identified. Conclusions: There has been a growth in the types of PROs in more recent years, and they were more frequently reported in RCTs. However, head/neck cancer trials with a combination of PROs and non-PROs were the most prevalent.  \nKEYWORDS  \nhead/neck cancer, methodological study, methods, randomized controlled trial, systematic review  \nendpoints for survival and locoregional control. Similarly, researchers treating tongue carcinoma with a combina-  \nPatient-reported outcomes (PROs) are pivotal in clinical research to understand whether therapies have in fact impacted the lives of patients. In contrast, relying only on outcomes from the perspective of the researcher provides a limited view of the potential impact of therapies. For example, Parmar et al.1 is a systematic review of compiled evidence on the effect of chemotherapy for treating oral and oropharyngeal cancer. However, it only reports  \ntion of surgical, radio, and chemical therapies have only reported data on survival and cancer recurrence.2 One example of PRO is pain or discomfort after an intervention was applied.3 Ideally, clinical studies should present a mixture of PROs and non-PROs to provide a more com  \nprehensive view of the effects of proposed therapies.  \nIn the head and neck areas, the use of PROs is even more critical in oncology due to the devastating potential  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine. 2024;13:e7036 .  \n[https://doi.org/10.1002/cam4.7036](https://doi.org/10.1002/cam4.7036)  \n[wileyonlinelibrary.com/journal/cam4](wileyonlinelibrary.com/journal/cam4)  \n1 of 10  \nside effects of conventional therapies, such as chemotherapy and radiotherapy, which may be long-lasting or even permanent.4 To the best of our knowledge, a comprehensive overview of the types of outcomes in randomized controlled trials (RCTs) of interventions for treating head and neck cancers has not yet been published.  \nThe objective of the present study was to provide a comprehensive mapping of non-PROs and PROs in RCTs involving the treatment of head and neck neoplasms. We also evaluated whether there was a temporal trend in reporting different types of outcomes.  \n2 | METHODS  \n2.1 | Research question  \nThe following research questions were used to guide the conduct of the present study: (1)","cbCaibmT793QCRZk","https://ap.wps.com/l/cbCaibmT793QCRZk","pdf",454802,"English","# Introduction\n## Abstract\n# Methods\n## Research question\n## Eligibility criteria\n## Definition of non-PROs and PROs\n## Data search and selection","[{\"question\":\"What was the study’s primary objective regarding head and neck cancer trials?\",\"answer\":\"To map and assess how frequently patient-reported outcomes (PROs) and non-PROs appear in randomized controlled trials for head/neck cancers, including whether reporting changed over time.\"},{\"question\":\"How were studies and follow-up periods selected for inclusion?\",\"answer\":\"Randomized controlled trials of interventions for head/neck cancers were included, with supportive and side-effect-related interventions also considered. When multiple follow-ups existed, the article with the longest follow-up was chosen, while other designs and non-English articles were excluded.\"},{\"question\":\"What trends in PRO and non-PRO reporting were observed over the 20-year period?\",\"answer\":\"The frequency of non-PROs fell from 40% to 22%, while PROs increased from 5% to 19%. Reporting that included both PROs and non-PROs remained relatively stable, ranging from 55% to 58%.\"}]","Review of patient-reported outcomes (PROs) and non-PROs in randomized controlled trials addressing head/neck cancers | PDF",1790013950,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b3da904134f1f541ceca522a1dba76b.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa11c4aa8e75bceca8c5cac9f12577ba.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8091a939ba9e2bceebaf9e8f0e44ba80.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba0bfc06de937b4259ee1a983e4b32b2.webp",980,1287]